Institut Pasteur Korea, DNDi Partner in Neglected Diseases Screening Effort | GenomeWeb

NEW YORK (GenomeWeb News) – The international non-profit Drugs for Neglected Diseases Initiative (DNDi) and the Institut Pasteur Korea (IP-K) will collaborate to screen for and examine molecules that may be used as new treatments for certain "neglected" diseases, IP-K said today.

The two-year research agreement will focus on studying molecules that could be developed into treatments for leishmaniasis, which kills around 20,000 to 30,000 people per year, and Chagas disease, which affects around seven to eight million people every year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: a sequencing-based screen of Lyme disease-causing pathogen, the range of animals bitten by Anopheles darling mosquitoes in Peru, and more.

An NC State researcher is exploring the use of CRISPR-Cas3 as an anti-microbial, Gizmodo reports.

The Earth BioGenome Project plans to sequence all life on Earth, according to ScienceInsider.

For those who are concerned about Trump administration actions related to science, a new column in Scientific American has suggestions for ways to fight back.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.